Halozyme Therapeutics reported $73.71M in Pre-Tax Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US USD -26415000 7.15M
Agios Pharmaceuticals AGIO:US USD -81747000 10.06M
Alnylam Pharmaceuticals ALNY:US USD -329357000 54.68M
Amarin AMRN:US USD -3883000 60.92M
Aptinyx Inc APTX:US USD -15303000 2.36M
Cara Therapeutics CARA:US USD -23180000 18.97M
Cytokinetics CYTK:US USD -142310000 122.49M
Esperion Therapeutics ESPR:US USD -55117000 11.21M
Halozyme Therapeutics HALO:US USD 73.71M 21.78M
Immunogen IMGN:US USD -77755000 15.73M
Intercept Pharmaceuticals ICPT:US USD -104087000 83.77M
Intra Cellular Therapies ITCI:US USD -53507000 33.1M
Intrexon XON:US USD -7694000 18.45M
Mannkind MNKD:US USD -14432000 14.59M
Minerva Neurosciences NERV:US USD -6901000 1.82M
Nektar Therapeutics NKTR:US USD -59204000 99.76M
Peregrine Pharmaceuticals PPHM:US USD 2.27M 1.68M
Pfizer PFE:US USD 10.67B 3.11B
Rigel Pharmaceuticals RIGL:US USD -19037000 5.54M
United Therapeutics UTHR:US USD 312.5M 161.9M
Vanda Pharmaceuticals VNDA:US USD 5.46M 1.67M